Steven Altmann

Statistics

Publications

Citations

196

H-Index

Active since

2007

Affiliations

Amgen (United States)(Current)

Steven Altmann is an author at Amgen (United States) specializing in pharmacology, optimization of pharmacodynamic properties, and medicinal chemistry.

Publications per year

2007–2017

Publications

Pharmacological inhibition of PARP-1 reduces α-synuclein- and MPP+-induced cytotoxicity in Parkinson’s disease in vitro models

Tiago F. Outeiro, Tom N. Grammatopoulos, Steven Altmann et al. · Biochemical and Biophysical Research Communications · 2007 · 78 citations

Life Sciences, Neuroscience, Pharmacology +17

Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity

Russell F. Graceffa, Alessandro A. Boezio, Jessica Able et al. · Journal of Medicinal Chemistry · 2017 · 69 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Sulfonamides as Selective Na<sub>V</sub>1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities

Matthew M. Weiss, Thomas A. Dineen, Isaac E. Marx et al. · Journal of Medicinal Chemistry · 2017 · 49 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

1–3 of 3